Novo Nordisk CEO Open to NYSE Direct Listing, Replacing ADRs

Novo Nordisk's CEO signaled openness to a direct listing on the NYSE, which would replace its current ADR structure. The move reflects the company's strategic focus on the US market, which accounts for over half of revenue, amid competitive pressure from Eli Lilly in the weight-loss drug space. A direct listing would be a significant corporate governance and capital markets shift, potentially affecting share liquidity and investor base.